collaboration - Molecure

OncoArendi Therapeutics supervisory board welcomes international biopharmaceutical experts: Nancy Van Osselaer, Paul van der Horst and Rafal Kamiński as its new members

OncoArendi Therapeutics supervisory board welcomes international biopharmaceutical experts: Nancy Van Osselaer, Paul van der Horst and Rafal Kamiński as its new members Appointments bring global leadership experience and expertise in drug discovery, as well as clinical

OncoArendi continues to grow by executing further steps of the strategy and initiates two new drug discovery programs within its existing research platforms

According to the strategy released in March, OncoArendi Therapeutics S.A. (WSE: OAT) expands its existing innovative drug discovery platforms by launching two new programs: CHIT1 SELECTIVE focusing on new therapeutic areas within the chitinase platform and

OncoArendi continues to grow by executing further steps of the strategy and initiates two new drug discovery programs within its existing research platforms

According to the strategy released in March, OncoArendi Therapeutics S.A. (WSE: OAT) expands its existing innovative drug discovery platforms by launching two new programs: CHIT1 SELECTIVE focusing on new therapeutic areas within the chitinase platform and

OncoArendi executes the strategy for 2021-2025 in the area of R&D platform for developing small molecules modulating RNA function

· On June 16 2021, the Company signed a scientific cooperation agreement with the International Institute of Molecular and Cell Biology in Warsaw (IIMCB) in the field of discovery and development of small molecule drugs modulating

OncoArendi executes the strategy for 2021-2025 in the area of R&D platform for developing small molecules modulating RNA function

· On June 16 2021, the Company signed a scientific cooperation agreement with the International Institute of Molecular and Cell Biology in Warsaw (IIMCB) in the field of discovery and development of small molecule drugs modulating

Drug Candidate OATD-01 may find use in treatment of pulmonary fibrosis in patients who have survived a new coronavirus infection (COVID-19)

Potential effectiveness of OATD-01 in the treatment of pulmonary fibrosis is based on a unique mechanism of inhibiting a new biological target – chitotriosidase 1 (CHIT1)Linking COVID-19 infection to pulmonary fibrosis where CHIT1 plays a role

Drug Candidate OATD-01 may find use in treatment of pulmonary fibrosis in patients who have survived a new coronavirus infection (COVID-19)

Potential effectiveness of OATD-01 in the treatment of pulmonary fibrosis is based on a unique mechanism of inhibiting a new biological target – chitotriosidase 1 (CHIT1)Linking COVID-19 infection to pulmonary fibrosis where CHIT1 plays a role

New Head of Research (Chief Scientific Officer) at OncoArendi

OncoArendi has recently hired dr. Rafał Kamiński for the position of Chief Scientific Officer. He has acquired broad international experience in discovery and development of innovative small molecule drugs and management of scientific teams from previous

New Head of Research (Chief Scientific Officer) at OncoArendi

OncoArendi has recently hired dr. Rafał Kamiński for the position of Chief Scientific Officer. He has acquired broad international experience in discovery and development of innovative small molecule drugs and management of scientific teams from previous

Search Results for: collaboration

OncoArendi Therapeutics supervisory board welcomes international biopharmaceutical experts: Nancy Van Osselaer, Paul van der Horst and Rafal Kamiński as its new members

OncoArendi continues to grow by executing further steps of the strategy and initiates two new drug discovery programs within its existing research platforms

OncoArendi continues to grow by executing further steps of the strategy and initiates two new drug discovery programs within its existing research platforms

OncoArendi executes the strategy for 2021-2025 in the area of R&D platform for developing small molecules modulating RNA function

OncoArendi executes the strategy for 2021-2025 in the area of R&D platform for developing small molecules modulating RNA function

Drug Candidate OATD-01 may find use in treatment of pulmonary fibrosis in patients who have survived a new coronavirus infection (COVID-19)

Drug Candidate OATD-01 may find use in treatment of pulmonary fibrosis in patients who have survived a new coronavirus infection (COVID-19)

New Head of Research (Chief Scientific Officer) at OncoArendi

New Head of Research (Chief Scientific Officer) at OncoArendi